Peptide profile
LL-37
Cathelicidin peptide for innate immunity
Compare LL-37 with other peptides →Summary
A tiny body-made protein that fights germs and helps your body's defense team.
- Typical dose
- 0.1-0.5mg Daily
- Route
- Subcutaneous
- Cycle length
- 14-30 days
- Evidence
- Anecdotal
Mechanism
How it works
LL-37 acts like a multi-tool for your immune system — it punches holes in bacteria, signals reinforcements, and rebuilds tissue.
Cathelicidin-derived antimicrobial peptide disrupting microbial membranes, modulating chemokines, and promoting angiogenesis via FPRL1.
Reported in research
Benefits
- Fights many different kinds of germs
- Helps your body's defense team work better
- Helps cuts and wounds heal
Context, not a prescription
Dosing
- Typical range
- 0.1-0.5mg Daily (Subcutaneous)
- Cycle length
- 14-30 days
Safety
Side effects & contraindications
Possible side effects
- Injection site pain
- Mild fever
- Temporary fatigue
- Allergic reaction
- Headache
- Nausea
Contraindications
- Pregnancy or breastfeeding
- Autoimmune conditions (theoretical risk)
- Known hypersensitivity
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Your defense team gets more alert. You get sick less easily. Your wounds heal better.
How it works
LL-37 is like a handy multi-tool for your body's defenses. It pokes holes in germs, calls for backup, and fixes up tissue.
It grabs onto special spots on cells. It also breaks open the outside of germs.
What to expect
You may feel defense effects in 3-7 days.
- Days 3-7: Your body's defense team gets more alert.
- Weeks 2-3: You get sick from germs less easily.
- Weeks 3-4: Your body heals better.
Good to know
- Start with a very small dose (0.05mg)
- Watch out for any allergic reactions
- Keep your use short (14 days)
Staying safe
- Sore spot where you got the shot
- Mild fever
- Feeling tired for a little while
Avoid if you have:
- People who are pregnant or breastfeeding
- People whose defense team attacks their own body (a maybe risk)
- People who are allergic to it
Mechanism of action
Cathelicidin-derived antimicrobial peptide disrupting microbial membranes, modulating chemokines, and promoting angiogenesis via FPRL1.
Binds to formyl peptide receptors and disrupts pathogen cell membranes.
Pharmacodynamics
Immune effects within 3-7 days.
Enhanced immune surveillance, reduced infection susceptibility, improved wound healing.
Timeline
- Days 3-7: Enhanced immune surveillance.
- Weeks 2-3: Reduced infection susceptibility.
- Weeks 3-4: Improved tissue healing.
Comparisons
- LL-37 — effectiveness Emerging, safety Emerging, cost $$, Medium to use
- Thymosin Alpha-1 — effectiveness High, safety Excellent, cost $$, Easy to use
Adverse effects
Common:
- Injection site pain
- Mild fever
- Temporary fatigue
Rare:
- Allergic reaction
- Headache
- Nausea
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Autoimmune conditions (theoretical risk)
- Known hypersensitivity
- Start with very low dose (0.05mg)
- Monitor for allergic response
- Keep cycle short (14 days)
Qué hace
Tu equipo de defensa se vuelve más alerta. Te enfermas con menos facilidad. Tus heridas sanan mejor.
Cómo funciona
LL-37 es como una práctica herramienta multiusos para las defensas de tu cuerpo. Les hace agujeros a los gérmenes, pide refuerzos y repara tejidos.
Se une a puntos especiales en las células. También rompe la parte exterior de los gérmenes.
Qué esperar
Puedes notar efectos en tu sistema de defensa en 3-7 días.
- Días 3-7: El sistema de defensa de tu cuerpo se vuelve más alerta.
- Semanas 2-3: Te enfermas menos fácilmente por los gérmenes.
- Semanas 3-4: Tu cuerpo sana mejor.
Bueno saber
- Comenzar con una dosis muy pequeña (0.05 mg)
- Vigilar cualquier reacción alérgica
- Mantener el uso breve (14 días)
Manteniéndose seguro
- Zona dolorida donde te aplicaste la inyección
- Fiebre leve
- Sentirse cansado por un tiempo
Evitar si tienes:
- Personas embarazadas o en lactancia
- Personas cuyo sistema de defensa ataca su propio cuerpo (riesgo posible)
- Personas que sean alérgicas a él
Mecanismo de acción
Péptido antimicrobiano derivado de la catelicidina que altera las membranas microbianas, modula las quimiocinas y promueve la angiogénesis a través de FPRL1.
Se une a los receptores de péptidos formil y altera las membranas celulares de los patógenos.
Farmacodinamia
Efectos inmunitarios en 3-7 días.
Vigilancia inmunitaria mejorada, menor susceptibilidad a infecciones, cicatrización de heridas mejorada.
Cronología
- Días 3-7: Vigilancia inmunitaria mejorada.
- Semanas 2-3: Menor susceptibilidad a infecciones.
- Semanas 3-4: Cicatrización de tejidos mejorada.
Comparaciones
- LL-37 — efectividad Emergente, seguridad Emergente, costo $$, Media de usar
- Thymosin Alpha-1 — efectividad Alta, seguridad Excelente, costo $$, Fácil de usar
Efectos adversos
Comunes:
- Dolor en el sitio de inyección
- Fiebre leve
- Fatiga temporal
Raros:
- Reacción alérgica
- Dolor de cabeza
- Náuseas
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Enfermedades autoinmunes (riesgo teórico)
- Hipersensibilidad conocida
- Comenzar con dosis muy baja (0.05 mg)
- Vigilar respuesta alérgica
- Mantener ciclo corto (14 días)
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 14-30 days
FAQ
Common questions
Is LL-37 safe for long-term use?
Long-term safety data is limited as it is still in research stages.
What is the evidence level?
This compound is classified as Anecdotal. Evidence relies primarily on self-reported user experiences. Controlled studies are lacking.
Research
Research & sources
Current evidence for LL-37 is rated as Anecdotal. No controlled clinical research is available.
- 1. LL-37 antimicrobial activity (2008) — DOI:10.1038/nri2435
- 2. LL-37 antimicrobial activity (2008)